

ESMO Preceptorship on Non-Small-Cell Lung Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**HELSINKI FINLAND
22-23 MAY 2024**

Co-Chairs

Pasi A. Jänne, United States
Solange Peters, Switzerland

ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Helsinki, Finland
22-23 May 2024

CO-CHAIRS

Pasi A. Jänne, United States
Solange Peters, Switzerland

SPEAKERS

| | |
|--|---------------------------------|
| Haseem Ashraf, Norway | Keith M. Kerr, United Kingdom |
| Odd Terje Brustugun, Norway | Karin Lindberg, Sweden |
| Alessandra Curioni-Fontecedro, Switzerland | Patrick Micke, Sweden |
| Inger Johanne Zwicky Eide, Norway | Jan Nyman, Sweden |
| Enriqueta Felip, Spain | Noemi Reguart, Spain |
| Åslaug Helland, Norway | Egbert F. Smit, The Netherlands |
| Ilkka Ilonen, Finland | Jens Benn Sørensen, Denmark |

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology, histo-prognostic and molecular factors, and liquid biopsies in the management of NSCLC
- To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC, and obtain some highlights of ongoing clinical research

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 22 May 2024

| | | |
|---------------------------|---|--|
| 09:00-09:10 10' | Opening and welcome | |
| 10' | Introduction and objectives | Pasi A. Jänne, US Solange Peters, CH |
| 09:10-10:05 55' | SESSION 1 Screening, diagnosis, and staging | Chair: Solange Peters, CH |
| 20' | Early detection of lung cancer: Biology, screening and cost-effectiveness | Haseem Ashraf, NO |
| 20' | The role of pathology and genetic/molecular analyses for primary cancer diagnostics | Patrick Micke, SE |
| 15' | Q&A | All |
| 10:05-10:35 | Coffee break | |
| 10:35-11:15 40' | SESSION 2 Adjuvant therapy | Chair: Pasi A. Jänne, US |
| 25' | Adjuvant and neo-adjuvant chemotherapy, radiotherapy targeted and immunotherapeutic agents: Clinical evidence and clinical research | Enriqueta Felip, ES |
| 15' | Q&A | All |
| 11:15-11:55 40' | SESSION 3 Multidisciplinary lung tumour board – Part I | Chair: Pasi A. Jänne, US |
| 40' | Management of stage III - Case presentation <ul style="list-style-type: none"> - Surgeon's point of view - Radiotherapist's point of view - Medical oncologist's point of view - Discussion | Inger Johanne Zwicky Eide, NO Åslaug Helland, NO Ilkka Ilonen, FI Jan Nyman, SE |
| 11:55-12:35 40' | SESSION 4 Multidisciplinary lung tumour board – Part II | Chair: Solange Peters, CH |
| 40' | Management of oligometastatic disease - Case presentation <ul style="list-style-type: none"> - Surgeon's point of view - Radiotherapist's point of view - Medical oncologist's point of view - Discussion | Ilkka Ilonen, FI Karin Lindberg, SE Jens Benn Sørensen, DK |
| 12:35-13:35 | Lunch | |
| 13:35-14:45 70' | SESSION 5 Audience cases | Chairs: Pasi A. Jänne, US Solange Peters, CH |
| 70' | Participants clinical case discussion (7x10') | Faculty |
| 14:45-15:15 | Coffee break | |
| 15:15-16:10 55' | SESSION 6 Systemic therapy for advanced NSCLC | Chair: Pasi A. Jänne, US |
| 20' | Immune Checkpoint Inhibitors as a consolidation in stage III NSCLC | Åslaug Helland, NO |
| 20' | Immune Checkpoint Inhibitors across lines of metastatic NSCLC | Solange Peters, CH |
| 15' | Q&A | All |
| 20:00 | Networking dinner | |

Thursday, 23 May 2024

| | | |
|----------------------------|---|---|
| 08:30-10:25 115' | SESSION 7 Targeted therapies | Chair: Solange Peters, CH |
| 20' | Systemic therapy for non-oncogene addicted NSCLC, including ADC | Egbert F. Smit, NL |
| 20' | New treatment options for EGFR-mutated NSCLC | Pasi A. Jänne, US |
| 20' | New treatment options for ALK-ROS1 rearranged NSCLC | Alessandra Curioni-Fontecedro, CH |
| 20' | KRAS mutant NSCLC | Odd Terje Brustugun, NO |
| 20' | RET/TRK/BRAF/MET | Noemi Reguart, ES |
| 15' | Q&A | All |
| 10:25-10:55 | Coffee break | |
| 10:55-11:25 30' | SESSION 8 Audience cases | Chairs: Pasi A. Jänne, US Solange Peters, CH |
| 30' | Participants clinical case discussion (3x10') | Faculty |
| 11:25-13:00 95' | SESSION 9 Other thoracic tumours and molecular testing | Chair: Pasi A. Jänne, US |
| 20' | Optimal platform and sequence for biomarker testing in advanced NSCLC: IHC, PCR, NGS and more | Keith M. Kerr, UK |
| 20' | Liquid biopsy applications in the early detection and management of NSCLC patients | Odd Terje Brustugun, NO |
| 20' | Immunotherapy for SCLC | Noemi Reguart, ES |
| 20' | Immunotherapy for mesothelioma | Alessandra Curioni-Fontecedro, CH |
| 15' | Q&A | All |
| 13:00-13:10 10' | Conclusion and take-home messages | Pasi A. Jänne, US Solange Peters, CH |
| 13:10-14:10 | Lunch | |

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion